Safety finding weighs on Pfizer's inflammation drug, and could spell trouble for others
Bio Pharma Dive
JANUARY 27, 2021
A large safety study found that patients given Pfizer's Xeljanz had health issues like major heart complications and cancer at a higher rate than those who got a different kind of anti-inflammation drug.
Let's personalize your content